Sharon Barbari Net Worth

The estimated Net Worth of Sharon Barbari is at least $245 mil dollars as of 20 August 2020. Ms. Barbari owns over 75,000 units of Sonoma Pharmaceuticals stock worth over $245,250 and over the last 20 years she sold SNOA stock worth over $0. In addition, she makes $0 as Independent Director at Sonoma Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Barbari SNOA stock SEC Form 4 insiders trading

Sharon has made over 1 trades of the Sonoma Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 75,000 units of SNOA stock worth $111,000 on 20 August 2020.

The largest trade she's ever made was exercising 75,000 units of Sonoma Pharmaceuticals stock on 20 August 2020 worth over $111,000. On average, Sharon trades about 2,143 units every 0 days since 2004. As of 20 August 2020 she still owns at least 75,000 units of Sonoma Pharmaceuticals stock.

You can see the complete history of Ms. Barbari stock trades at the bottom of the page.

Sharon Barbari biography

Sharon Barbari serves as Independent Director of the Company. Ms. Barbari has served as our director and audit committee financial expert since March 2014. Since June 2020, she has served on the board of directors of Agile Therapeutics. Since January 2019, she is also serving as a board member for Menlo Therapeutics Ltd. (formerly Foamix Pharmaceuticals Ltd.). From July 2009 to July 2017, Ms. Barbari served as Executive Vice President of Finance and Chief Financial Officer of Cytokinetics, Inc. She also served as Senior Vice President of Finance and Chief Financial Officer from September 2004 through June 2009. From September 2002 to August 2004, Ms. Barbari was the Chief Financial Officer and Senior Vice President of Finance and Administration of InterMune, Inc., a biopharmaceutical company. From January 1998 to June 2002, she served at Gilead Sciences, Inc., a biopharmaceutical company, and held several positions of increasing responsibility including most recently as its Vice President and Chief Financial Officer. From 1996 to 1998, Ms. Barbari served as Vice President of Strategic Planning at Foote, Cone & Belding Healthcare in San Francisco, an international advertising and marketing firm. From 1972 to 1995, she was employed by Syntex Corporation where she held various management positions in corporate finance, financial planning, marketing, and commercial planning.

How old is Sharon Barbari?

Sharon Barbari is 66, she's been the Independent Director of Sonoma Pharmaceuticals since 2014. There are 2 older and 8 younger executives at Sonoma Pharmaceuticals. The oldest executive at Sonoma Pharmaceuticals Inc. is Jay Birnbaum, 75, who is the Independent Director.

What's Sharon Barbari's mailing address?

Sharon's mailing address filed with the SEC is 500 COLLEGE ROAD EAST, SUITE 310, , PRINCETON, NJ, 08540.

Insiders trading at Sonoma Pharmaceuticals

Over the last 8 years, insiders at Sonoma Pharmaceuticals have traded over $0 worth of Sonoma Pharmaceuticals stock and bought 25,155 units worth $125,359 . The most active insiders traders include Frederick J Sandford, Sharon Barbari, eRobert E Miller. On average, Sonoma Pharmaceuticals executives and independent directors trade stock every 27 days with the average trade being worth of $4,840. The most recent stock trade was executed by Robert E Miller on 12 March 2018, trading 2,400 units of SNOA stock currently worth $9,744.

What does Sonoma Pharmaceuticals do?

sonoma pharmaceuticals, inc., develops and produces stabilized hypochlorous acid (hocl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the united states and internationally. the company offers epicyn, an antimicrobial facial cleanser; levicyn, a hypochlorous acid (hocl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; sebuderm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and ceramax, a lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as loyon for the management of skin scal

Complete history of Ms. Barbari stock trades at Agile Therapeutics Inc, Cytokinetics Inc, Sonoma Pharmaceuticals, eMenlo Therapeutics

Sonoma Pharmaceuticals executives and stock owners

Sonoma Pharmaceuticals executives and other stock owners filed with the SEC include:

• Bruce Thornton,
  Chief Operating Officer, Secretary
• Bruce Thornton,
  COO & Corp. Sec.
• Amy M. Trombly,
  CEO & Pres
• Amy Trombly,
  Chief Executive Officer
• Jerome Dvonch,
  Chief Financial Officer
• Philippe Weigerstorfer,
  Independent Director
• Jay Birnbaum,
  Independent Director
• Sharon Barbari,
  Independent Director
• Jerry McLaughlin,
  Lead Independent Director
• Jerry Dvonch,
  Chief Financial Officer
• Victoria Covel,
  Assistant Controller
• Dr. Robert Northey,
  Exec. VP of R&D
• Russell Joseph Harrison,
  Director
• John Mclaughlin,
  Director
• Marc Umscheid,
  Chief Strategy/Mkt Officer
• Robert Grant Edwards,
  Chief Financial Officer
• Poggetto John Dal,
  Controller
• Robert Allen Northey,
  Exec. VP of Res & Development
• James J Schutz,
  
• Robert E Miller,
  
• Frederick J Sandford,
  CEO and Interim CFO
• Chad Norman White,
  Chief Financial Officer
• Jerome J Dvonch,
  Chief Financial Officer